Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Merck Raises 2026 Outlook as Keytruda Growth Drives Q3 Beat

Oct 29, 2026, 6:49 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong beat on both EPS and revenue, plus higher 2026 guidance and a sizable Qlex contribution imply a positive price re-rating. The one-time charge weighs on margins but is offset by core growth and product diversification; patent expiry risk remains a longer-term consideration.

AI summary

What happened, with direct paths to the underlying reporting

Merck topped Q3 estimates and raised its adjusted EPS outlook to $2.77–$2.82, while narrowing 2026 revenue guidance. Growth was led by Keytruda and the newer Qlex injector, which posted $830M in quarterly sales. Gardasil demand and Winrevair performance contributed to a robust top-line, underscoring diversification beyond Keytruda.

Merck beat Q3 estimates; raised adjusted EPS to $2.77-$2.82. Prior guidance was $2.66-$2.76.
Keytruda sales reached $8.60B; Qlex contributed $830M in Q3, highest since 2025.
2026 revenue guidance narrowed to $66.8B-$67.3B; includes a $400M one-time charge.
Gardasil demand strong in the US; Winrevair sales up 93% to $694M; total revenue $18.09B.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Merck Raises 2026 Outlook as Keytruda Growth Drives Q3 Beat

Merck's Endometrial Cancer Trial Signals Potential MRK Drug Upside

Merck- Moderna vaccine makes manufacturing faster; Keytruda strategy under study

Merck Expands Cancer Pipeline with Up to $2.13B SciBrunch Licensing

Merck Eye-Disease Trial Clears Primary Endpoint, Potential MRK Upside